Christopher Seet, M.D.
$100,000 Career Development Grant
Research Title: Identifying Novel Mechanisms of Immune Evasion in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, and new treatment approaches are urgently needed. Immunotherapy has emerged as a safe and effective treatment for certain solid tumors, however the development of effective immunotherapies for AML requires a better understanding of the mechanisms by which leukemia evades the immune system. AML is associated with selective dysregulation of antigen presenting cells (APCs), which are a vital component of anti-tumor immune responses. The study will investigate mechanisms by which leukemia cells interfere with APC development with the goal of identifying novel immunotherapeutic targets in AML.